RESUMEN
It remains unclear how interleukin-21 receptor (IL-21R) contributes to type 1 diabetes. Here we have shown that dendritic cells (DCs) in the pancreas required IL-21R not for antigen uptake, but to acquire the chemokine receptor CCR7 and migrate into the draining lymph node. Consequently, less antigen, major histocompatibility complex (MHC) class II, and CD86 was provided to autoreactive effector cells in Il21r(-/-) mice, impairing CD4(+) T cell activation, CD40:CD40L interactions, and pancreatic infiltration by autoreactive T cells. CD40 crosslinking restored defective CD4(+) cell expansion and CD4 independently expanded autoreactive CD8(+) cells, but CD8(+) cells still required CD4(+) cells to reach the pancreas and induce diabetes. Diabetes induction by transferred T cells required IL-21R-sufficient host antigen-presenting cells. Transferring IL-21R-sufficient DCs broke diabetes resistance in Il21r(-/-) mice. We conclude that IL-21R controls both antigen transport by DCs and the crucial beacon function of CD4(+) cells for autoreactive CD8(+) cells to reach the islets.
Asunto(s)
Autoinmunidad/inmunología , Diabetes Mellitus Tipo 1/inmunología , Subunidad alfa del Receptor de Interleucina-21/fisiología , Islotes Pancreáticos/inmunología , Subgrupos de Linfocitos T/inmunología , Traslado Adoptivo , Animales , Presentación de Antígeno , Linfocitos T CD4-Positivos/inmunología , Antígenos CD40/inmunología , Ligando de CD40/inmunología , Linfocitos T CD8-positivos/inmunología , Quimiotaxis de Leucocito , Diabetes Mellitus Tipo 1/patología , Modelos Animales de Enfermedad , Resistencia a la Enfermedad , Subunidad alfa del Receptor de Interleucina-21/deficiencia , Subunidad alfa del Receptor de Interleucina-21/genética , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/patología , Activación de Linfocitos , Cooperación Linfocítica , Virus de la Coriomeningitis Linfocítica , Ratones , Ratones Endogámicos NOD , Receptores CCR7/metabolismo , Organismos Libres de Patógenos Específicos , Bazo/inmunología , Subgrupos de Linfocitos T/trasplanteRESUMEN
Type 1 diabetes (T1D) is a chronic autoimmune disease in which destruction or damaging of the beta-cells in the islets of Langerhans results in insulin deficiency and hyperglycemia. We only know for sure that autoimmunity is the predominant effector mechanism of T1D, but may not be its primary cause. T1D precipitates in genetically susceptible individuals, very likely as a result of an environmental trigger. Current genetic data point towards the following genes as susceptibility genes: HLA, insulin, PTPN22, IL2Ra, and CTLA4. Epidemiological and other studies suggest a triggering role for enteroviruses, while other microorganisms might provide protection. Efficacious prevention of T1D will require detection of the earliest events in the process. So far, autoantibodies are most widely used as serum biomarker, but T-cell readouts and metabolome studies might strengthen and bring forward diagnosis. Current preventive clinical trials mostly focus on environmental triggers. Therapeutic trials test the efficacy of antigen-specific and antigen-nonspecific immune interventions, but also include restoration of the affected beta-cell mass by islet transplantation, neogenesis and regeneration, and combinations thereof. In this comprehensive review, we explain the genetic, environmental, and immunological data underlying the prevention and intervention strategies to constrain T1D.
Asunto(s)
Diabetes Mellitus Tipo 1/genética , Animales , Ensayos Clínicos como Asunto , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/terapia , Predisposición Genética a la Enfermedad , Humanos , Estado Prediabético/diagnóstico , Prevención PrimariaRESUMEN
The biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is able to promote the generation of tolerogenic mature dendritic cells (mDCs) with an impaired ability to activate autoreactive T cells. These cells could represent a reliable tool for the promotion or restoration of Ag-specific tolerance through vaccination strategies, for example in type 1 diabetes patients. However, successful transfer of 1,25(OH)2D3-treated mDCs (1,25D3-mDCs) depends on the capacity of 1,25(OH)2D3 to imprint a similar tolerogenic profile in cells derived from diabetes-prone donors as from diabetes-resistant donors. In this study, we examined the impact of 1,25(OH)2D3 on the function and phenotype of mDCs originating from healthy (C57BL/6) and diabetes-prone (NOD) mice. We show that 1,25(OH)2D3 is able to imprint a phenotypic tolerogenic profile on DCs derived from both mouse strains. Both NOD- and C57BL/6-derived 1,25D3-mDCs decreased the proliferation and activation of autoreactive T cells in vitro, despite strain differences in the regulation of cytokine/chemokine expression. In addition, 1,25D3-mDCs from diabetes-prone mice expanded CD25(+)Foxp3(+) regulatory T cells and induced intracellular IL-10 production by T cells in vitro. Furthermore, 1,25D3-mDCs exhibited an intact functional migratory capacity in vivo that favors homing to the liver and pancreas of adult NOD mice. More importantly, when cotransferred with activated CD4(+) T cells into NOD.SCID recipients, 1,25D3-mDCs potently dampened the proliferation of autoreactive donor T cells in the pancreatic draining lymph nodes. Altogether, these results argue for the potential of 1,25D3-mDCs to restore Ag-specific immune tolerance and arrest autoimmune disease progression in vivo.
Asunto(s)
Células Dendríticas/inmunología , Tolerancia Inmunológica/efectos de los fármacos , Vitamina D/análogos & derivados , Animales , Quimiotaxis de Leucocito/efectos de los fármacos , Quimiotaxis de Leucocito/inmunología , Células Dendríticas/citología , Células Dendríticas/efectos de los fármacos , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Tolerancia Inmunológica/inmunología , Activación de Linfocitos/efectos de los fármacos , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos NOD , Ratones Transgénicos , Fenotipo , Reacción en Cadena en Tiempo Real de la Polimerasa , Vitamina D/farmacologíaRESUMEN
Inflammatory mechanisms play a key role in the pathogenesis of type 1 and type 2 diabetes. IL6, a pleiotropic cytokine with impact on immune and non-immune cell types, has been proposed to be involved in the events causing both forms of diabetes and to play a key role in experimental insulin-dependent diabetes development. The aim of this study was to investigate how beta-cell specific overexpression of IL-6 influences diabetes development. We developed two lines of rat insulin promoter (RIP)-lymphocytic choriomeningitis virus (LCMV) mice that also co-express IL6 in their beta-cells. Expression of the viral nucleoprotein (NP), which has a predominantly intracellular localization, together with IL6 led to hyperglycemia, which was associated with a loss of GLUT-2 expression in the pancreatic beta-cells and infiltration of CD11b(+) cells, but not T cells, in the pancreas. In contrast, overexpression of the LCMV glycoprotein (GP), which can localize to the surface, with IL-6 did not lead to spontaneous diabetes, but accelerated virus-induced diabetes by increasing autoantigen-specific CD8(+) T cell responses and reducing the regulatory T cell fraction, leading to increased pancreatic infiltration by CD4(+) and CD8(+) T cells as well as CD11b(+) and CD11c(+) cells. The production of IL-6 in beta-cells acts prodiabetic, underscoring the potential benefit of targeting IL6 in diabetes.
Asunto(s)
Diabetes Mellitus Experimental/inmunología , Células Secretoras de Insulina/inmunología , Interleucina-6/inmunología , Virus de la Coriomeningitis Linfocítica/inmunología , Nucleoproteínas/inmunología , Animales , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/patología , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/patología , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/patología , Regulación de la Expresión Génica/genética , Regulación de la Expresión Génica/inmunología , Transportador de Glucosa de Tipo 2/genética , Transportador de Glucosa de Tipo 2/inmunología , Hiperglucemia/inmunología , Células Secretoras de Insulina/patología , Interleucina-6/genética , Virus de la Coriomeningitis Linfocítica/genética , Ratones , Ratones Transgénicos , Nucleoproteínas/genética , RatasRESUMEN
It is thought that viral infections might jeopardize regulatory T cell therapy in type 1 diabetes. Viral infections can lead to surface expression of ligands for the activating NKG2D receptor, such as retinoic acid early transcript 1 (Rae-1), whose expression on beta-cells recruits NKG2D(+) autoreactive CD8(+) T cells. Both in men and mice, autoreactive cytotoxic T cells express NKG2D. We showed that NKG2D expression increased on CD4(+) and CD8(+) T cells during virus-induced diabetes development in the rat insulin promotor (RIP) Lymphocytic Choriomeningitis Virus (LCMV) model. Combination treatment with anti-NKG2D and antigen-specific regulatory T cells (Treg), at doses inefficacious in mono-treatment, synergized to prevent diabetes in 75% of the virus-infected RIP-LCMV mice. Nevertheless, NKG2D blockade alone failed to reverse recent-onset diabetes in non-obese diabetic (NOD) mice, despite downregulation of NKG2D on NK cells in the blood and CD8(+) T cells in the spleen and pancreatic lymph nodes. Our data suggest that blocking the interaction of NKG2D with it ligands is insufficient to protect against diabetes when a strong inflammatory process actively drives NKG2D upregulation, but should be considered to help maintaining Treg functionality during ongoing pancreatic inflammation.
Asunto(s)
Diabetes Mellitus Tipo 1/prevención & control , Coriomeningitis Linfocítica/inmunología , Virus de la Coriomeningitis Linfocítica/inmunología , Subfamilia K de Receptores Similares a Lectina de Células NK/metabolismo , Linfocitos T Reguladores/inmunología , Animales , Anticuerpos/inmunología , Linfocitos T CD8-positivos/inmunología , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/virología , Células Asesinas Naturales/inmunología , Ganglios Linfáticos/inmunología , Ratones , Ratones Endogámicos NOD , Subfamilia K de Receptores Similares a Lectina de Células NK/inmunología , Proteínas Asociadas a Matriz Nuclear/biosíntesis , Proteínas de Transporte Nucleocitoplasmático/biosíntesis , Páncreas/inmunología , Páncreas/virología , Bazo/inmunologíaRESUMEN
Recent studies have shown that IL-17 can contribute beneficially to pathogen defense but also that excessive IL-17 levels are associated with chronic inflammation and autoimmune disorders. To date, the role of IL-17 in viral infections and type 1 diabetes is ambiguous. In this study, we used IL-17A enhanced green fluorescent protein bicistronic reporter mouse strains to analyze in situ production of IL-17A. Upon Klebsiella pneumoniae bacterial infection, CD4(+) and γδ T cells produce IL-17A. In contrast, CD4(+) or CD8(+) T cells do not produce IL-17A in response to acute or protracted viral infection with lymphocytic choriomeningitis virus or during autoimmune diabetes development in the CD8-driven lymphocytic choriomeningitis virus-induced model of type 1 diabetes. We conclude that viral elimination and type 1 diabetes can occur in the absence of detectable IL-17A production, suggesting IL-17A is not essential in these settings.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Diabetes Mellitus Tipo 1/inmunología , Interleucina-17/inmunología , Virosis/inmunología , Animales , Linfocitos T CD4-Positivos , Separación Celular , Modelos Animales de Enfermedad , Femenino , Citometría de Flujo , Técnicas de Sustitución del Gen , Genes Reporteros , Proteínas Fluorescentes Verdes/genética , Virus de la Coriomeningitis Linfocítica/inmunología , Masculino , Ratones , Ratones Endogámicos C57BLRESUMEN
Redirection of immune responses by manipulation of antigen-presenting cells is an emerging strategy for immunosuppressive treatment of autoimmune diseases. In vivo expansion of dendritic cells (DC) by Fms-like tyrosine kinase-3 (Flt3)-Ligand (FL) treatment was shown to delay diabetes onset in the NOD model of autoimmune diabetes. However, we show here that Flt3 stimulation actually accelerates autoimmunity when autoreactive CD8 T cells are detectable in blood prior to treatment. With autoreactive CD8 cells present, the capacity of FL to expand DCs and induce Treg remained intact, but both numbers and the functional response of islet-specific CD8s were boosted. Also, the inhibitory receptor PD-1 on (autoreactive) CD8 T cells and its ligand PD-L1 on Treg were no longer upregulated. These data highlight the need to pre-screen for T cell autoreactivity prior to generalized DC expansion and illustrate how accelerated disease can occur when the intended initiation of regulatory mechanisms is impaired later in diabetogenesis.
Asunto(s)
Autoinmunidad , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Proteínas de la Membrana/uso terapéutico , Animales , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/inmunología , Proliferación Celular , Células Dendríticas/citología , Humanos , Islotes Pancreáticos/inmunología , Ratones , Ratones Endogámicos NOD , Linfocitos T Reguladores/citología , Resultado del TratamientoRESUMEN
The emergence of regulatory T cells (Tregs) as central mediators of peripheral tolerance in the immune system has led to an important area of clinical investigation to target these cells for the treatment of autoimmune diseases such as type 1 diabetes. We have demonstrated earlier that in vitro treatment of T cells from healthy individuals with TX527, a low-calcemic analog of bioactive vitamin D, can promote a CD4+ CD25high CD127low regulatory profile and imprint a migratory signature specific for homing to sites of inflammation. Towards clinical application of vitamin D-induced Tregs in autologous adoptive immunotherapy for type 1 diabetes, we show here that 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and TX527 similarly imprint T cells from type 1 diabetes patients with a CD4+ CD25high CD127low regulatory profile, modulate surface expression of skin- and inflammation-homing receptors, and increase expression of CTLA-4 and OX-40. Also, 1,25(OH)2D3 and TX527 treatment inhibit the production of effector cytokines IFN-γ, IL-9, and IL-17. Importantly, 1,25(OH)2D3 and TX527 promote the induction of IL-10-producing CD4+ CD25high CD127low T cells with a stable phenotype and the functional capacity to suppress proliferation of autologous responder T cells in vitro. These findings warrant additional validation of vitamin D-induced Tregs in view of future autologous adoptive immunotherapy in type 1 diabetes.
Asunto(s)
Alquinos/farmacología , Calcitriol/farmacología , Diferenciación Celular/efectos de los fármacos , Colecalciferol/farmacología , Diabetes Mellitus Tipo 1/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Diferenciación Celular/inmunología , Humanos , Fenotipo , Linfocitos T/inmunología , Linfocitos T Reguladores/inmunologíaRESUMEN
High doses of the active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], prevent diabetes in the NOD mouse but also elicit unwanted calcemic side effects. Because immune cells themselves can convert vitamin D3 into 1,25(OH)2D3 locally, we hypothesized that dietary vitamin D3 can also prevent disease. Thus, we evaluated whether dietary administration of high doses of regular vitamin D3 (800 IU/day) during different periods of life (pregnancy and lactation, early life [3-14 weeks of age], or lifelong [3-35 weeks of age]) safely prevents diabetes in NOD mice. We found that only lifelong treatment raised serum 25-hydroxyvitamin D3 from 173 nmol/L in controls to 290 nmol/L, without inducing signs of calcemic or bone toxicity, and significantly reduced diabetes development in both male and female NOD mice. This diabetes protection by vitamin D3 correlated with preserved pancreatic insulin content and improved insulitis scores. Moreover, vitamin D3 treatment decreased interferon-γ-positive CD8(+) T cells and increased CD4(+)(CD25(+))FoxP3(+) T cells in pancreatic draining lymph nodes. In conclusion, this study shows for the first time that high doses of regular dietary vitamin D3 can safely prevent diabetes in NOD mice when administered lifelong, although caution is warranted with regards to administering equivalently high doses in humans.
Asunto(s)
Colecalciferol/administración & dosificación , Colecalciferol/farmacología , Diabetes Mellitus Tipo 1/prevención & control , Vitaminas/administración & dosificación , Vitaminas/farmacología , Animales , Diabetes Mellitus Tipo 1/inmunología , Suplementos Dietéticos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Inmunoterapia Adoptiva , Activación de Linfocitos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos NOD , Linfocitos T Reguladores/efectos de los fármacos , Factores de TiempoRESUMEN
Growing insight into the pathogenesis of type 1 diabetes (T1D) and numerous studies in preclinical models highlight the potential of antigen-specific approaches to restore tolerance efficiently and safely. Oral administration of protein antigens is a preferred method for tolerance induction, but degradation during gastrointestinal passage can impede such protein-based therapies, reducing their efficacy and making them cost-ineffective. To overcome these limitations, we generated a tolerogenic bacterial delivery technology based on live Lactococcus lactis (LL) bacteria for controlled secretion of the T1D autoantigen GAD65370-575 and the anti-inflammatory cytokine interleukin-10 in the gut. In combination with short-course low-dose anti-CD3, this treatment stabilized insulitis, preserved functional ß-cell mass, and restored normoglycemia in recent-onset NOD mice, even when hyperglycemia was severe at diagnosis. Combination therapy did not eliminate pathogenic effector T cells, but increased the presence of functional CD4(+)Foxp3(+)CD25(+) regulatory T cells. These preclinical data indicate a great therapeutic potential of orally administered autoantigen-secreting LL for tolerance induction in T1D.
Asunto(s)
Autoantígenos/farmacología , Diabetes Mellitus/inmunología , Glutamato Descarboxilasa/farmacología , Interleucina-10/metabolismo , Fragmentos de Péptidos/farmacología , Administración Oral , Envejecimiento , Animales , Autoantígenos/administración & dosificación , Autoantígenos/inmunología , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/metabolismo , Regulación de la Expresión Génica , Glutamato Descarboxilasa/administración & dosificación , Interleucina-10/genética , Lactococcus lactis , Ratones , Ratones Endogámicos NOD , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/inmunología , Linfocitos T Reguladores/efectos de los fármacosRESUMEN
The beneficial effects of vitamin D supplementation for several health-related issues, including the prevention of diabetes, are a topic of intense discussion. Data from epidemiological studies suggest a correlation between vitamin D deficiency and higher prevalence of both type 1 and type 2 diabetes (T1D and T2D). In animal models, vitamin D deficiency predisposes to diabetes whereas vitamin D supplementation prevents disease. Nevertheless, well-designed clinical intervention studies are lacking. We discuss here the evidence for a role of vitamin D in diabetes and propose that vitamin D deficiency should be avoided, especially in all at-risk people. This should be possible by implementing global guidelines and by focusing on daily dietary supplementation with small doses of vitamin D.
Asunto(s)
Diabetes Mellitus/prevención & control , Vitamina D/sangre , Animales , Diabetes Mellitus/sangre , Diabetes Mellitus/etiología , Suplementos Dietéticos , Humanos , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/prevención & controlRESUMEN
Due to its critical role in NK cell differentiation and CD8(+) T cell homeostasis, the importance of IL-15 is more firmly established for cytolytic effectors of the immune system than for CD4(+) T cells. The increased levels of IL-15 found in several CD4(+) T cell-driven (auto-) immune diseases prompted us to examine how IL-15 influences murine CD4(+) T cell responses to low dose TCR-stimulation in vitro. We show that IL-15 exerts growth factor activity on both CD4(+) and CD8(+) T cells in a TCR-dependent and Cyclosporin A-sensitive manner. In CD4(+) T cells, IL-15 augmented initial IL-2-dependent expansion and once IL-15Rα was upregulated, IL-15 sustained the TCR-induced expression of IL-2/15Rß, supporting proliferation independently of secreted IL-2. Moreover, IL-15 counteracts CD4(+) T cell suppression by a gradually expanding CD25(High)CD4(+) T cell subset that expresses Foxp3 and originates from CD4(+)CD25(+) Tregs. These in vitro data suggest that IL-15 may dramatically strengthen the T cell response to suboptimal TCR-triggering by overcoming an activation threshold set by Treg that might create a risk for autoimmune pathology.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Interleucina-15/farmacología , Receptores de Antígenos de Linfocitos T/inmunología , Linfocitos T Reguladores/inmunología , Animales , Antígenos CD/genética , Antígenos CD/inmunología , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD8-positivos/citología , Linfocitos T CD8-positivos/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Ciclosporina/farmacología , Citometría de Flujo , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/inmunología , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/inmunología , Humanos , Tolerancia Inmunológica , Interleucina-15/inmunología , Subunidad alfa del Receptor de Interleucina-15/genética , Subunidad alfa del Receptor de Interleucina-15/inmunología , Interleucina-2/biosíntesis , Interleucina-2/metabolismo , Subunidad beta del Receptor de Interleucina-2/genética , Subunidad beta del Receptor de Interleucina-2/inmunología , Activación de Linfocitos/efectos de los fármacos , Ratones , Receptores de Antígenos de Linfocitos T/metabolismo , Transducción de Señal/efectos de los fármacos , Linfocitos T Reguladores/citología , Linfocitos T Reguladores/efectos de los fármacosRESUMEN
Current interventions for arresting autoimmune diabetes have yet to strike the balance between sufficient efficacy, minimal side effects, and lack of generalized immunosuppression. Introduction of antigen via the gut represents an appealing method for induction of antigen-specific tolerance. Here, we developed a strategy for tolerance restoration using mucosal delivery in mice of biologically contained Lactococcus lactis genetically modified to secrete the whole proinsulin autoantigen along with the immunomodulatory cytokine IL-10. We show that combination therapy with low-dose systemic anti-CD3 stably reverted diabetes in NOD mice and increased frequencies of local Tregs, which not only accumulated in the pancreatic islets, but also suppressed immune response in an autoantigen-specific way. Cured mice remained responsive to disease-unrelated antigens, which argues against excessive immunosuppression. Application of this therapeutic tool achieved gut mucosal delivery of a diabetes-relevant autoantigen and a biologically active immunomodulatory cytokine, IL-10, and, when combined with a low dose of systemic anti-CD3, was well tolerated and induced autoantigen-specific long-term tolerance, allowing reversal of established autoimmune diabetes. Therefore, we believe this method could be an effective treatment strategy for type 1 diabetes in humans.
Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Tolerancia Inmunológica , Lactococcus lactis/genética , Animales , Autoantígenos/biosíntesis , Autoantígenos/genética , Complejo CD3/inmunología , Recuento de Células , Proliferación Celular , Terapia Combinada , Diabetes Mellitus Tipo 1/inmunología , Humanos , Hipoglucemiantes/uso terapéutico , Factores Inmunológicos/uso terapéutico , Terapia de Inmunosupresión , Insulina/metabolismo , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/patología , Interleucina-10/biosíntesis , Interleucina-10/genética , Interleucina-10/metabolismo , Mucosa Intestinal , Lactococcus lactis/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos NOD , Proinsulina/biosíntesis , Proinsulina/genética , Proinsulina/metabolismo , Linfocitos T Reguladores/metabolismo , Linfocitos T Reguladores/fisiologíaRESUMEN
Vitamin D is a steroid hormone that is acquired via diet or synthesized in the skin upon UV exposure and needs subsequent hydroxylation steps to become activated as 1,25-dihydroxyvitamin D. While widely known for its role in maintaining bone health, vitamin D receptors have also been identified in different immune cell types. Many immune cells can also convert vitamin D into its bioactive form, thus enhancing the locally available concentrations to those required for the immunomodulatory effects of vitamin D. In this review, we summarize the genetic and epidemiologic data potentially linking vitamin D to autoimmune, infectious and allergic diseases. We also discuss how vitamin D influences the immune responses in each of those conditions based on the data generated using patient samples or preclinical models of each of these diseases.
Asunto(s)
Enfermedades Autoinmunes/etiología , Hipersensibilidad/etiología , Sistema Inmunológico/metabolismo , Infecciones/epidemiología , Deficiencia de Vitamina D/fisiopatología , Vitamina D/metabolismo , Animales , Enfermedades Autoinmunes/terapia , Humanos , Hipersensibilidad/terapia , Sistema Inmunológico/fisiopatología , Inmunomodulación , Infecciones/terapia , Factores de Riesgo , Vitamina D/uso terapéuticoRESUMEN
T and NK cell subsets play a crucial role in the immune surveillance designed to fend off dangerous pathogens while leaving endogenous cells untouched. However, occasionally T cells do initiate an attack against self and are therefore termed autoreactive. Moreover, both NK and T cells can be stimulated by danger signals released by cells under "stress", i.e. infection, ongoing necrotic cell death, etc. Consequently, the inappropriate triggering of danger signals, or a failure to switch these off once the immune response has been resolved, can have serious consequences for the host. Ligands for the activating receptor NKG2D (natural killer group 2 member D) are such key danger signals that are presented by "stressed" cells. In this review, we discuss the current knowledge on NKG2D and its ligands in the context of autoimmune diseases and immune-mediated diseases that inadvertently target endogenous cells and/or tissue.